Ninety percent of cancer-related deaths are due to metastatic (stage IV) disease, when the malignant cells spread throughout the body interfering with organ function leading to organ failure and death.

Our mission is to develop interventions that will finally lead to real cancer cures. Combining our state-of-the-art cell-based technologies with innovative diagnostic, prognostic, and drug development strategies, we are developing comprehensive personalized interventions to combat stage IV cancers.